Evolus (EOLS) News Today → You won't believe what Citigroup just did to it's depositors (From American Alternative) (Ad) Free EOLS Stock Alerts $12.63 +0.12 (+0.96%) (As of 05/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 28 at 1:52 AM | americanbankingnews.comReviewing Evolus (NASDAQ:EOLS) and Clever Leaves (NASDAQ:CLVR)May 27 at 6:42 AM | marketbeat.comTrexquant Investment LP Purchases 67,678 Shares of Evolus, Inc. (NASDAQ:EOLS)Trexquant Investment LP increased its position in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) by 74.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 158,075 shares of the company's stock after buying an addiMay 25, 2024 | marketbeat.comBNP Paribas Financial Markets Purchases 127,541 Shares of Evolus, Inc. (NASDAQ:EOLS)BNP Paribas Financial Markets grew its position in Evolus, Inc. (NASDAQ:EOLS - Free Report) by 137.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 220,399 shares of the company's stock after acquiringMay 24, 2024 | markets.businessinsider.comBarclays Reaffirms Their Buy Rating on Evolus (EOLS)May 22, 2024 | markets.businessinsider.comStrong Buy Rating for Evolus Backed by Growth Potential and Market Penetration ProspectsMay 22, 2024 | seekingalpha.comEvolus: Chiseling Away At The Aesthetic MarketMay 22, 2024 | americanbankingnews.comEvolus (NASDAQ:EOLS) Stock Rating Reaffirmed by HC WainwrightMay 21, 2024 | marketbeat.comHC Wainwright Reiterates Buy Rating for Evolus (NASDAQ:EOLS)HC Wainwright reissued a "buy" rating and issued a $27.00 price target on shares of Evolus in a report on Tuesday.May 20, 2024 | stockhouse.comEvolus Announces Positive Data from Pivotal Trial for First Two Evolysse(TM) Dermal Filler Products at 2024 SCALE MeetingMay 20, 2024 | businesswire.comEvolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE MeetingMay 16, 2024 | insidertrades.comDavid N. Gill Sells 3,643 Shares of Evolus, Inc. (NASDAQ:EOLS) StockMay 16, 2024 | finance.yahoo.comDirector Vikram Malik Sells 28,000 Shares of Evolus Inc (EOLS)May 16, 2024 | finance.yahoo.comDirector David Gill Sells 10,361 Shares of Evolus Inc (EOLS)May 15, 2024 | insidertrades.comEvolus, Inc. (NASDAQ:EOLS) CFO Sandra Beaver Sells 2,423 SharesMay 15, 2024 | finance.yahoo.comEvolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women’s Wear Daily Beauty CEO SummitMay 15, 2024 | businesswire.comEvolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women's Wear Daily Beauty CEO SummitMay 14, 2024 | marketbeat.comInsider Selling: Evolus, Inc. (NASDAQ:EOLS) CFO Sells 2,423 Shares of StockEvolus, Inc. (NASDAQ:EOLS - Get Free Report) CFO Sandra Beaver sold 2,423 shares of the firm's stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $12.72, for a total transaction of $30,820.56. Following the transaction, the chief financial officer now owns 151,778 shares of the company's stock, valued at approximately $1,930,616.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.May 13, 2024 | markets.businessinsider.comBarclays Keeps Their Buy Rating on Evolus (EOLS)May 10, 2024 | finance.yahoo.comEvolus’ Sandra Beaver Named Orange County Business Journal’s Public Company CFO of the YearMay 10, 2024 | businesswire.comEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 10, 2024 | businesswire.comEvolus' Sandra Beaver Named Orange County Business Journal's Public Company CFO of the YearMay 10, 2024 | markets.businessinsider.comEvolus’s Strong Q1 Performance and Solid Growth Trajectory Justify Buy RatingMay 10, 2024 | markets.businessinsider.comEvolus Outperforms Expectations with Strong Q1 Sales and Promising Growth TrajectoryMay 9, 2024 | finance.yahoo.comEvolus First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsMay 8, 2024 | finance.yahoo.comEvolus, Inc. (NASDAQ:EOLS) Q1 2024 Earnings Call TranscriptMay 8, 2024 | marketbeat.comEvolus (NASDAQ:EOLS) Given Buy Rating at HC WainwrightHC Wainwright restated a "buy" rating and issued a $27.00 target price on shares of Evolus in a research report on Wednesday.May 8, 2024 | finance.yahoo.comEvolus Inc (EOLS) (Q1 2024) Earnings Call Transcript Highlights: Strong Growth and Strategic ...May 7, 2024 | investorplace.comEOLS Stock Earnings: Evolus Beats EPS, Beats Revenue for Q1 2024May 7, 2024 | finance.yahoo.comEvolus Inc (EOLS) Q1 2024 Earnings: Surpasses Revenue Estimates with Significant GrowthMay 7, 2024 | businesswire.comEvolus Reports First Quarter 2024 Results and Provides Business UpdateMay 3, 2024 | finance.yahoo.comThe 15% return this week takes Evolus' (NASDAQ:EOLS) shareholders one-year gains to 59%April 30, 2024 | marketbeat.comEvolus (EOLS) Scheduled to Post Earnings on TuesdayEvolus (NASDAQ:EOLS) will be releasing earnings after the market closes on Tuesday, May 7, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=588133)April 23, 2024 | businesswire.comEvolus to Report First Quarter Financial Results on May 7, 2024April 18, 2024 | investing.comEvolus reports 6-month efficacy of Jeuveau in glabellar lines studyApril 17, 2024 | finance.yahoo.comEvolus Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra-Strength" 40U Formulation of Jeuveau®April 17, 2024 | businesswire.comEvolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®April 16, 2024 | marketbeat.comEvolus, Inc. (NASDAQ:EOLS) Sees Significant Decrease in Short InterestEvolus, Inc. (NASDAQ:EOLS - Get Free Report) was the target of a significant drop in short interest during the month of March. As of March 31st, there was short interest totalling 4,650,000 shares, a drop of 6.6% from the March 15th total of 4,980,000 shares. Based on an average trading volume of 657,700 shares, the short-interest ratio is currently 7.1 days. Approximately 9.8% of the company's shares are sold short.April 13, 2024 | marketbeat.comVanguard Group Inc. Grows Stock Holdings in Evolus, Inc. (NASDAQ:EOLS)Vanguard Group Inc. grew its holdings in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) by 37.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,698,647 shares of the company's stock after buying an additApril 12, 2024 | businesswire.comEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 10, 2024 | marketbeat.comNeedham & Company LLC Reaffirms "Buy" Rating for Evolus (NASDAQ:EOLS)Needham & Company LLC reissued a "buy" rating and issued a $22.00 price target on shares of Evolus in a report on Wednesday.April 9, 2024 | marketbeat.comEvolus, Inc. (NASDAQ:EOLS) is Stonepine Capital Management LLC's Largest PositionStonepine Capital Management LLC lifted its stake in Evolus, Inc. (NASDAQ:EOLS - Free Report) by 3.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,333,004 shares of the company's stock after purchasingApril 6, 2024 | finance.yahoo.comEvolus, Inc. (NASDAQ:EOLS) is favoured by institutional owners who hold 57% of the companyApril 3, 2024 | marketbeat.comEvolus (NASDAQ:EOLS) Shares Gap Down to $13.76Evolus (NASDAQ:EOLS) Shares Gap Down to $13.76March 30, 2024 | insidertrades.comInsider Selling: Evolus, Inc. (NASDAQ:EOLS) Insider Sells 6,236 Shares of StockMarch 29, 2024 | marketbeat.comEvolus, Inc. (NASDAQ:EOLS) Insider David Moatazedi Sells 6,236 SharesEvolus, Inc. (NASDAQ:EOLS - Get Free Report) insider David Moatazedi sold 6,236 shares of the company's stock in a transaction that occurred on Wednesday, March 27th. The shares were sold at an average price of $13.86, for a total transaction of $86,430.96. Following the transaction, the insider now owns 689,614 shares in the company, valued at approximately $9,558,050.04. The sale was disclosed in a filing with the SEC, which is available at this link.March 26, 2024 | finance.yahoo.comEvolus to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceMarch 24, 2024 | insidertrades.comEvolus, Inc. (NASDAQ:EOLS) CFO Sells $78,954.24 in StockMarch 21, 2024 | marketbeat.comInsider Selling: Evolus, Inc. (NASDAQ:EOLS) CFO Sells 5,672 Shares of StockEvolus, Inc. (NASDAQ:EOLS - Get Free Report) CFO Sandra Beaver sold 5,672 shares of the firm's stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $13.92, for a total transaction of $78,954.24. Following the sale, the chief financial officer now owns 154,201 shares in the company, valued at approximately $2,146,477.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.March 21, 2024 | msn.comEvolus (NASDAQ:EOLS): An Attractive Aesthetics Stock for Growth InvestorsMarch 20, 2024 | seekingalpha.comEvolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028 Get Evolus News Delivered to You Automatically Sign up to receive the latest news and ratings for EOLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Next President (Not Trump. Not Biden.) (Ad)Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be Trump. Click here to see why it will be ______ _________. EOLS Media Mentions By Week EOLS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EOLS News Sentiment▼0.880.82▲Average Medical News Sentiment EOLS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EOLS Articles This Week▼93▲EOLS Articles Average Week Get Evolus News Delivered to You Automatically Sign up to receive the latest news and ratings for EOLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Zentalis Pharmaceuticals News Today Viridian Therapeutics News Today Tango Therapeutics News Today Immunome News Today Humacyte News Today Arcturus Therapeutics News Today Stoke Therapeutics News Today ProKidney News Today PureTech Health News Today Aurinia Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EOLS) was last updated on 5/29/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaWrite this ticker symbol down…StocksToTradeMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceHe Is Giving Away BitcoinCrypto Swap ProfitsBill Clinton Backing Biden Replacement???The Freeport SocietyElon to Transform U.S. Economy? Porter & CompanyTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evolus, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
